delta-3-Carene is a bicyclic monoterpene hydrocarbon that appears prominently in several conifer, juniper, cypress, and angelica-root profiles already cataloged in AromaForge. Compared with many minor terpenes, its evidence base is moderate: identity and occurrence are strong, a 2018 RIFM safety assessment exists, and preclinical studies report antimicrobial, sleep-related, anti-inflammatory, and antinociceptive signals. Those findings are still mostly nonclinical, so archive copy should present delta-3-carene as a well-defined aromatic constituent with active preclinical research rather than as a medically established wellness ingredient.
Chemical identity and composition
PubChem resolves 3-carene to CID 26049 with formula C10H16 and the IUPAC name 3,7,7-trimethylbicyclo[4.1.0]hept-3-ene. In the AromaForge oil archive, delta-3-carene reaches very high levels in juniper whole oil, remains substantial in cypress leaf oil, and also appears as a notable secondary constituent in angelica root and several fir or spruce records. Public literature and safety review sources also place delta-3-carene in turpentine- and pine-associated exposure contexts, which matters because oxidation products rather than the neat hydrocarbon are repeatedly discussed in allergy literature.
Aroma and practical use
- Use the recorded piney, sweet, resinous, terpenic, resin descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Compare the recorded goal signals with the intended purpose, while keeping model assumptions separate from observed study outcomes.
- Review the flagged use concerns across every contributing oil and the selected dilution.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2019 Experimental Neurobiology study reported that oral 3-carene increased sleep duration and reduced sleep latency in the pentobarbital-induced sleep test, with evidence that it acted through GABAA-benzodiazepine receptors.
A 2019 Experimental Neurobiology study reported that oral 3-carene increased sleep duration and reduced sleep latency in the pentobarbital-induced sleep test, with evidence that it acted through GABAA-benzodiazepine receptors.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2019 Molecules study found antibacterial activity for 3-carene against Brochothrix thermosphacta and Pseudomonas fluorescens and reported membrane damage, metabolic disruption, and probable genomic-DNA structural effects in vitro.
A 2019 Molecules study found antibacterial activity for 3-carene against Brochothrix thermosphacta and Pseudomonas fluorescens and reported membrane damage, metabolic disruption, and probable genomic-DNA structural effects in vitro.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2024 Journal of Physiology and Pharmacology paper reported that 3-carene suppressed IL-4, IL-5, and IL-13 expression and reduced lung epithelial thickness in a murine asthma model.
A 2024 Journal of Physiology and Pharmacology paper reported that 3-carene suppressed IL-4, IL-5, and IL-13 expression and reduced lung epithelial thickness in a murine asthma model.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2025 Journal of Ethnopharmacology study reported that delta-3-carene, the major component of Schinus terebinthifolius essential oil, produced antinociceptive effects in mice that were reversed by methysergide, implicating serotonergic receptors.
A 2025 Journal of Ethnopharmacology study reported that delta-3-carene, the major component of Schinus terebinthifolius essential oil, produced antinociceptive effects in mice that were reversed by methysergide, implicating serotonergic receptors.
This experimental finding does not establish benefit, dose or safety in people using this blend.
How it contributes to goal calculations
Model markers guide the formulation score. They are separate from the source findings above.
Use concerns and concentration limits
Sensitization concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
A peer-reviewed RIFM fragrance ingredient safety assessment exists for delta-3-carene, which strengthens basic hazard-review coverage compared with many minor archive constituents.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
No direct public citation is attached to this entry.
Allergy literature summarized in a 2021 review points to delta-3-carene hydroperoxides, rather than the unoxidized parent terpene alone, as an important sensitizing issue in old turpentine exposure contexts.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
No constituent-specific topical maximum or consumer-use dermal limit was verified in the reviewed public sources for isolated delta-3-carene.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
gabaa benzodiazepine positive modulation signal
The 2019 Experimental Neurobiology paper reported that 3-carene prolonged inhibitory synaptic decay, its effects were reproduced by zolpidem, and flumazenil blocked them, supporting positive modulation at GABAA-benzodiazepine receptor sites in that model.
This experimental finding does not establish benefit, dose or safety in people using this blend.
No direct public citation is attached to this entry.
multifactor antibacterial membrane damage
The 2019 Molecules study reported membrane and cell-wall damage, leakage of intracellular contents, altered membrane potential, disrupted energy-metabolism enzymes, and likely DNA interaction in tested spoilage bacteria exposed to 3-carene.
This experimental finding does not establish benefit, dose or safety in people using this blend.
No direct public citation is attached to this entry.
cytokine suppression in allergic airway model
A 2024 murine asthma paper reported suppression of IL-4, IL-5, and IL-13 expression with reduced epithelial thickening after 3-carene treatment.
This experimental finding does not establish benefit, dose or safety in people using this blend.
No direct public citation is attached to this entry.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (5)
- Human clinical outcome data specific to isolated delta-3-carene were not verified in this pass.
- Most direct benefit-style evidence remains in vitro or animal-based, especially for antimicrobial, anti-inflammatory, and antinociceptive claims.
- A constituent-specific public dermal limit or IFRA-style use concentration was not confirmed from the reviewed sources.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.